A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Launched by DIZAL PHARMACEUTICALS · Mar 25, 2025

Keywords

ClinConnect Summary

This clinical trial, called TIAN-SHAN1, is studying a new oral medication named DZD6008 for patients with advanced non-small cell lung cancer (NSCLC) who have specific mutations in the EGFR gene. The main goals of the study are to find out how safe DZD6008 is and whether it can help shrink tumors in patients whose cancer has not responded well to previous treatments. The trial is currently not recruiting participants, but it is designed for adults aged 18 and older who have been diagnosed with advanced NSCLC and have documented EGFR mutations.

To be eligible for this study, patients must have already tried at least one EGFR-targeted treatment that didn’t work or caused side effects they couldn’t tolerate. They should also be in good overall health, with a suitable life expectancy of at least 12 weeks. Participants will provide tumor samples and receive the study drug under careful monitoring. It’s important to note that there are specific health conditions and recent treatments that could exclude someone from participating, so anyone interested should discuss their situation with their doctor to see if they might qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must be able to provide documented informed consent.
• • 2. Aged ≥ 18 years.
• • 3. Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced or metastatic, not suitable for curative therapy.
• • 4. Documentation of EGFR mutations from a local CLIA-certified laboratory (or equivalent). Part A: EGFR sensitizing mutations (Exon19del and/or L858R). Part B: EGFR sensitizing mutations (Exon19del and/or L858R) and C797X mutation.
• • 5. Provide adequate amount of pretreatment tumor samples collected after disease progression on the last EGFR TKI treatment.
• • 6. Failed (progressed or are intolerant) from at least 1 prior EGFR TKI regimen.
• • 7. ECOG 0 or 1 with predicted life expectancy ≥ 12 weeks.
• • 8. Patients with brain metastases must have a stable BM status.
• • 9. Measurable disease per RECIST 1.1.
• • 10. Adequate hematopoietic and other organ system functions.
• • 11. Male Patients with female partners of childbearing potential should use barrier contraceptives and refrain from donating sperm during their participation in this study and for 3 months following the last dose of the study drug.
• Exclusion Criteria:
• • 1. Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)(Part B).
• • 2. NSCLC with mixed small cell lung cancer (SCLC) or NSCLC with histologic SCLC transformation.
• • 3. Prior treatment with any of the following: 1)Immunotherapy or other antibody therapy within 4 weeks prior to the first administration; 2)Any cytotoxic chemotherapy, investigational drugs or other anticancer drugs from a previous treatment regimen or clinical study within 14 days prior to the first administration; 3)Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose, radiation to more than 30% of the bone marrow or with a wide field of radiation within 28 days before screening; 4)Currently receiving or unable to stop drug or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP)3A4. A washout period of at least 2 weeks for strong inhibitors and 3 weeks for strong inducers is required prior to the first study drug administration; 5)currently receiving or unable to stop drugs known to be CYP3A4 sensitive substrate with a narrow therapeutic index. A washout period of at least 14 days is required prior to the first study drug administration; 6)currently receiving or unable to stop drugs known to be proton pump inhibitors. A washout period of at least 7 days is required prior to the first study drug administration; 7)major surgery within 4 weeks of the first administration of DZD6008 or anticipated during the study period.
• • 4. Any unresolved toxicities from prior anti-cancer therapy greater than CTCAE Grade 1.
• • 5. Spinal cord compression or leptomeningeal metastasis.
• • 6. Patients with any other malignancy within 2 years of the first administration of study drug.
• • 7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses as judged by investigator.
• • 8. Patients with active infection, including but not limited to HBV, HCV, HIV and active infection of COVID-19.
• • 9. Resting QTcF \> 470 msec; Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG;Any factors that increase the risk of QTc prolongation.
• • 10. Past medical history of ILD or active ILD.
• • 11. Diseases which would preclude adequate absorption of DZD6008.
• • 12. Received a live vaccine within 2 weeks before the first administration of DZD6008.
• • 13. Women who are pregnant or breastfeeding.
• • 14. Hypersensitivity to active or inactive excipients of DZD6008.
• • 15. Involvement in the planning and conduct of the study.
• • 16. Judgment by the investigator that the patient is unlikely to comply with study procedures